Related Experiment Video
Updated: Feb 14, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Preclinical 203/212Pb-DOTA-Based Pretargeted Radioimmunotherapy in Nude Mice Bearing Established Human Colorectal
Brett A Vaughn1,2, Darren R Veach3,4, Daniela Burnes Vargas1,2
1Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, New York, New York.
Abstract:
The 203Pb (half-life [t1/2], 51.9 h) and 212Pb (t1/2 = 10.6 h) theranostic pair shows great potential for radiopharmaceutical therapy. We have developed a highly versatile pretargeted radioimmunotherapy (PRIT) platform that utilizes antitumor antigen/anti-DOTA bispecific antibodies (BsAbs) in combination with rapidly clearing, low-molecular-weight DOTA-radiohaptens (DOTA-PRIT). In this study, we tested the hypothesis that high-therapeutic index (TI) targeting of 212Pb (an in vivo generator of α-emitting progeny, specifically 212Bi (t1/2 = 1.01 h) and 212Po (t1/2 = 0.3 µs), and its imaging surrogate, 203Pb (γ-emitter, 279 keV), would be feasible with anti-glycoprotein A33 (GPA33) DOTA-PRIT for treatment of human colorectal cancer (CRC). Methods: For efficient and stable chelation of lead and high-affinity recognition by BsAbs, we synthesized a TCMC-based radiohapten precursor named TCMC-Proteus (TCMC-Pr). We prepared [212Pb]Pb-TCMC-Pr and confirmed its stability in vitro and recognition by BsAbs. Using the 203Pb analog, we conducted serial biodistribution and SPECT/CT imaging studies with a 3-step GPA33 DOTA-PRIT approach and extrapolated dosimetry for 212Pb. We then established anti-GPA33 212Pb-DOTA-PRIT in mouse xenografts of human CRC (GPA33-expressing SW1222). Results: TCMC-Pr was successfully radiolabeled with 203Pb/212Pb and verified stable in serum, and specific BsAb binding was confirmed. For GPA33-pretargeted [203Pb]Pb-TCMC-Pr, the blood, SW1222 tumor, and kidney uptakes at 24 h after injection were 0.27 ± 0.14 %IA/g, 8.04 ± 2.94 %IA/g, and 0.88 ± 0.14 %IA/g, respectively. 212Pb doses to tumor, blood, and kidneys were 12,723 mGy/MBq, 313 mGy/MBq (TI, 40.6), and 1,075 mGy/MBq (TI, 11.8), respectively. During 212Pb-DOTA-PRIT therapy studies, we established efficacy and identified a double-cycle treatment regimen (938 kBq + 938 kBq separated by 48 h; total, 1.88 MBq) that led to prolonged survival including 3 of 5 histologic cures at the study endpoint of 137 d. Mice in this treatment group exhibited normal bone marrows and moderate tubulointerstitial lesions, with overall preserved renal function. Conclusion: We have developed a safe, curative GPA33-targeted 212Pb-DOTA-PRIT treatment in a preclinical model of human CRC. This research underscores the potential of 203/212Pb-DOTA-PRIT in managing CRC and provides a road map for its modular application to other human tumor target antigens compatible with DOTA-PRIT.
Insights
This study developed a novel pretargeted radioimmunotherapy (PRIT) using lead-212 (212Pb) for colorectal cancer (CRC). The 212Pb-DOTA-PRIT treatment demonstrated safety and efficacy in preclinical models, offering a potential new therapy for CRC.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmaceutical Therapy
Background:
- The 203Pb/212Pb theranostic pair holds promise for radiopharmaceutical therapy.
- Pretargeted radioimmunotherapy (PRIT) using bispecific antibodies (BsAbs) and DOTA-radiohaptens offers a versatile platform.
- 212Pb acts as an in vivo generator of alpha-emitting progeny, ideal for targeted cancer therapy.
Purpose of the Study:
- To evaluate the efficacy of anti-glycoprotein A33 (GPA33) DOTA-PRIT using 203Pb for imaging and 212Pb for therapy in human colorectal cancer (CRC).
- To test the hypothesis that high-therapeutic index (TI) targeting with 203Pb/212Pb-DOTA-PRIT is feasible for CRC treatment.
Main Methods:
- Synthesis of a novel TCMC-based radiohapten precursor, TCMC-Proteus (TCMC-Pr), for stable lead chelation.
- Radiolabeling of TCMC-Pr with 203Pb and 212Pb, followed by in vitro stability and BsAb binding confirmation.
- Biodistribution, SPECT/CT imaging with 203Pb-DOTA-PRIT, dosimetry extrapolation for 212Pb, and therapeutic efficacy studies in mouse xenografts of human CRC.
Main Results:
- TCMC-Pr was successfully radiolabeled with 203Pb/212Pb and demonstrated stability in serum with specific BsAb binding.
- 203Pb-DOTA-PRIT showed favorable biodistribution in GPA33-expressing tumors with low uptake in healthy organs.
- 212Pb-DOTA-PRIT achieved significant tumor dose (12,723 mGy/MBq) with acceptable TI values for tumor, blood, and kidneys, leading to prolonged survival and histologic cures in mice.
Conclusions:
- A safe and curative GPA33-targeted 212Pb-DOTA-PRIT treatment was developed for preclinical human CRC models.
- 203/212Pb-DOTA-PRIT shows significant potential for CRC management.
- The modular DOTA-PRIT platform can be adapted for other tumor-associated antigens.
More Related Videos
Related Concept Videos
Azimuths and Bearings
Collar Bearings
Bearing Stress
Due to the intricacy of these microforces, an average value, known as bearing stress, is often used by...
Pivot Bearings
A pivot bearing is a specialized type of bearing designed to support axial loads on a rotating shaft. The bearing surface, or the pivot, is positioned at the end of a shaft to support the axial thrust. The pivot may...
Journal Bearings
To better understand the concept of journal bearings, consider a rope winch with dry or...
Bearings: Problem Solving

